The diagnostic value of brain natriuretic peptide in men with comorbid essential arterial hypertension and type 2 diabetes mellitus
DOI:
https://doi.org/10.14739/2310-1210.2020.5.214729Keywords:
brain natriuretic peptide, essential hypertension, type 2 diabetes mellitus, heart failureAbstract
The aim of the work is to investigate the diagnostic informativeness of brain natriuretic peptide (BNP) in men with left ventricular (LV) diastolic dysfunction (DD) and initial stages of chronic heart failure (CHF) in comorbid stage 2 essential hypertension (EH 2) and type 2 diabetes mellitus (T2DM).
Materials and methods. We examined 211 men. 79 people without signs of cardiovascular disease were assigned to a control group. 62 patients with EH 2 and CHF no higher than NYHA functional class (FC) I were included in the 1st, and 70 men with EH 2 combined with T2DM and CHF FC I–II formed the 2nd main study group. The plasma concentration of BNP was measured by ELISA. The examination included the determination of HbA1c, blood lipid profile, echocardiography. The mathematical processing was performed using the standard statistical package Statistica 6.1.
Results. Plasma levels of BNP in comorbid EH 2 and T2DM were significantly higher (102.18 ± 4.18 pg/ml) than those in patients with EH without T2DM (77.40 ± 2.85 pg/ml) and in subjects without cardiovascular diseases (21.74 ± 0.59 pg/ml) (P < 0.00001). According to the regression analysis, the level of BNP was associated with changes in parameters of intracardiac hemodynamics in patients with EH2. In patients with comorbid EH 2 and T2DM, the level of BNP was also associated with indicators of systemic hemodynamics and body weight. BNP as a marker of CHF at the recommended borderline level (35 pg/ml) in patients with EH 2 and T2DM was characterized by a sensitivity of 98.57 % and specificity of 55.32 %. The BNP borderline levels with higher specificity were determined for early diagnosis of CHF in EH 2 with T2DM and obesity comorbidities.
Conclusions. BNP, as an early marker of LV DD and the initial stages of CHF at the recommended borderline level in men with comorbid EH 2 and T2DM does not have sufficiently high specificity. In these pathological conditions, the determined borderline levels of BNP can be used as indicative surrogate markers for early diagnosis of CHF during screening with the view to identify persons for further echocardiographic additional examination and in cases where echocardiography is not possible.
References
Voronkov, L. H. (2014). «Shliakh» patsiienta z khronichnoiu sertsevoiu nedostatnistiu: yakomoha dovshyi, yakomoha komfortnishyi [«The way» of patients with chronic heart failure: as long as possible and as comfortable as possible]. Sertseva nedostatnist, (1), 7-10. [in Ukrainian].
Voronkov, L. G., Amosova, K. M., Dziak, G. V., Zharinov, O. J., Kovalenko, V. M., Korkushko, O. V., Nesukay, E. G., Sychov, O. S., Rudyk, Yu. S., & Parkhomenko, O. M. (2018). Rekomendatsii Asotsiatsii kardiolohiv Ukrainy z diahnostyky ta likuvannia khronichnoi sertsevoi nedostatnosti (2017) [Guidelines of the Ukraine Association of Cardiology for the Diagnosis and Treatment of Chronic Heart Failure (2017)]. Ukrainskyi kardiolohichnyi zhurnal, 25(3), 11-59. [in Ukrainian].
Mueller, C., McDonald, K., de Boer, R. A., Maisel, A., Cleland, J., Kozhuharov, N., Coats, A., Metra, M., Mebazaa, A., Ruschitzka, F., Lainscak, M., Filippatos, G., Seferovic, P. M., Meijers, W. C., Bayes-Genis, A., Mueller, T., Richards, M., Januzzi, J. L., Jr, & Heart Failure Association of the European Society of Cardiology. (2019). Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European Journal of Heart Failure, 21(6), 715-731. https://doi.org/10.1002/ejhf.1494
Voronkov, L. G., Berezin, O. E., Zharinova, V. Yu., Zhebel, V. M., Koval, O. A., Rudyk, Yu. S., Parkhomenko, O. M., & Tseluiko, V. Y. (2019). Biolohichni markery ta yikh zastosuvannia pry sertsevii nedostatnosti. Konsensus Vseukrainskoi asotsiatsii kardiolohiv Ukrainy, Vseukrainskoi asotsiatsii fakhivtsiv iz sertsevoi nedostatnosti ta Ukrainskoi asotsiatsii fakhivtsiv z nevidkladnoi kardiolohii [Biological markers and their use in heart failure. Consensus of Ukrainian Association of Cardiology, Ukrainian Heart Failure Association and Ukrainian Association on Acute Cardiovascular Care]. Ukrainskyi kardiolohichnyi zhurnal, 26(2), 11-22. [in Ukrainian]. http://doi.org/10.31928/1608-635X-2019.2.1122
Baldassarre, S., Fragapani, S., Panero, A., Fedele, D., Pinach, S., Lucchiari, M., Vitale, A. R., Mengozzi, G., Gruden, G., & Bruno, G. (2017). NTproBNP in insulin-resistance mediated conditions: overweight/obesity, metabolic syndrome and diabetes. The population-based Casale Monferrato Study. Cardiovascular Diabetology, 16(1), Article 119. https://doi.org/10.1186/s12933-017-0601-z
Krzesiński, P., Piechota, W., Piotrowicz, K., Gielerak, G., & Woźniak-Kosek, A. (2019). Association of Estimated Insulin Resistance with N-Terminal B-Type Natriuretic Peptide Concentration in Men with Metabolic Syndrome. Cardiology Research and Practice, 2019, Article 8571795. https://doi.org/10.1155/2019/8571795
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., McCoy, R. G., Mentz, R. J., PiÑa, I. L., American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, & Heart Failure Society of America. (2019). Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. Journal of Cardiac Failure, 25(8), 584-619. https://doi.org/10.1016/j.cardfail.2019.05.007
Tanase, D. M., Radu, S., Al Shurbaji, S., Baroi, G. L., Florida Costea, C., Turliuc, M. D., Ouatu, A., & Floria, M. (2019). Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications. International Journal of Molecular Sciences, 20(11), Article 2629. https://doi.org/10.3390/ijms20112629
Redfield, M. M., Rodeheffer, R. J., Jacobsen, S. J., Mahoney, D. W., Bailey, K. R., & Burnett, J. C. (2002). Plasma brain natriuretic peptide concentration: impact of age and gender. Journal of the American College of Cardiology, 40(5), 976-982. https://doi.org/10.1016/s0735-1097(02)02059-4
Clerico, A., Masotti, S., Musetti, V., & Passino, C. (2019). Pathophysiological mechanisms determining sex differences in circulating levels of cardiac natriuretic peptides and cardiac troponins. Journal of Laboratory and Precision Medicine, 4, Article 8. https://doi.org/10.21037/jlpm.2019.01.03
Kim, H. L., Kim, M. A., Choi, D. J., Han, S., Jeon, E. S., Cho, M. C., Kim, J. J., Yoo, B. S., Shin, M. S., Seong, I. W., Ahn, Y., Kang, S. M., Kim, Y. J., Kim, H. S., Chae, S. C., Oh, B. H., Lee, M. M., Ryu, K. H., & Korean Heart Failure Registry. (2017). Gender Difference in the Prognostic Value of N-Terminal Pro-B Type Natriuretic Peptide in Patients With Heart Failure. A Report From the Korean Heart Failure Registry (KorHF). Circulation Journal, 81(9), 1329-1336. https://doi.org/10.1253/circj.CJ-16-1345
Svennberg, E., Lindahl, B., Berglund, L., Eggers, K. M., Venge, P., Zethelius, B., Rosenqvist, M., Lind, L., & Hijazi, Z. (2016). NT-proBNP is a powerful predictor for incident atrial fibrillation - Validation of a multimarker approach. International Journal of Cardiology, 223, 74-81. https://doi.org/10.1016/j.ijcard.2016.08.001
Sobhani, K., Nieves Castro, D. K., Fu, Q., Gottlieb, R. A., Van Eyk, J. E., & Noel Bairey Merz, C. (2018). Sex differences in ischemic heart disease and heart failure biomarkers. Biology of Sex Differences, 9(1), Article 43. https://doi.org/10.1186/s13293-018-0201-y
Romiti, G. F., Recchia, F., Zito, A., Visioli, G., Basili, S., & Raparelli, V. (2020). Sex and Gender-Related Issues in Heart Failure. Heart Failure Clinics, 16(1), 121-130. https://doi.org/10.1016/j.hfc.2019.08.005
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., Kahan, T., Mahfoud, F., Redon, J., Ruilope, L., Zanchetti, A., Kerins, M., Kjeldsen, S. E., Kreutz, R., Laurent, S., Lip, G., … ESC Scientific Document Group. (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 39(33), 3021-3104. https://doi.org/10.1093/eurheartj/ehy339
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J., Coats, A., Falk, V., González-Juanatey, J. R., Harjola, V. P., Jankowska, E. A., Jessup, M., Linde, C., Nihoyannopoulos, P., Parissis, J. T., Pieske, B., Riley, J. P., Rosano, G., Ruilope, L. M., Ruschitzka, F., Rutten, F. H., … ESC Scientific Document Group. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 37(27), 2129-2200. https://doi.org/10.1093/eurheartj/ehw128
Seferovic, P. M., Ponikowski, P., Anker, S. D., Bauersachs, J., Chioncel, O., Cleland, J., de Boer, R. A., Drexel, H., Ben Gal, T., Hill, L., Jaarsma, T., Jankowska, E. A., Anker, M. S., Lainscak, M., Lewis, B. S., McDonagh, T., Metra, M., Milicic, D., Mullens, W., Piepoli, M. F., … Coats, A. (2019). Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 21(10), 1169-1186. https://doi.org/10.1002/ejhf.1531
Ministry of Health of Ukraine. (2012, December 21). Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry tsukrovomu diabeti 2 typu [On approval and implementation of medical technological documents for the standardization of medical care for type 2 diabetes mellitus (No. 1118)]. https://zakon.rada.gov.ua/rada/show/v1118282-12#Text
Shorikov, Ye. I. (2016). Markery endotelialnoi dysfunktsii ta remodeliuvannia sertsia ta sudyn pry hipertonichnii khvorobi, poiednanii iz tsukrovym diabetom 2 typu: henetychni, morfofunktsionalni, hemostaziolohichni ta farmakoekonomichni determinanty likuvannia. (Avtoref. dis. … doc. med. nauk). [Markers of endothelial dysfunction and remodeling of the heart and blood vessels in hypertension associated with type 2 diabetes: genetic, morphofunctional, hemostasiological and pharmacoeconomic determinants of treatment. Dr. med. sci. diss.]. Ternopil. [in Ukrainian].
Nagueh, S. F., Smiseth, O. A., Appleton, C. P., Byrd, B. F., 3rd, Dokainish, H., Edvardsen, T., Flachskampf, F. A., Gillebert, T. C., Klein, A. L., Lancellotti, P., Marino, P., Oh, J. K., Popescu, B. A., & Waggoner, A. D. (2016). Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography, 29(4), 277-314. https://doi.org/10.1016/j.echo.2016.01.011
Kovalenko, V. M., Sychov, O. S., Dolzhenko, M. M., Ivaniv, Yu. A., Deiak, S. I., Potashev, S. V., & Nosenko, N. M. (2016, October 20). Rekomendatsii z ekhokardiohrafichnoi otsinky diastolichnoi funktsii livoho shlunochka [Recommendations for echocardiographic evaluation of left ventricular diastolic function]. Webcardio.org. http://www.webcardio.org/rekomendatsiji-z-ekhokardioghrafichnoji-otsinky-diastolichnoji-funktsiji-livogho-shlunochka.aspx [in Ukrainian].
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., Di Mario, C., Ferreira, J. R., Gersh, B. J., Gitt, A. K., Hulot, J. S., Marx, N., Opie, L. H., Pfisterer, M., Prescott, E., Ruschitzka, F., … Zamorano, J. L. (2013). 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal, 34(38), 2949-3003. https://doi.org/10.1093/eurheartj/eht296
Ruzhanskaya, V. O., Sivak, V. G., Sakovych, O. O., Pashkova, J. P., & Zhebel, V. M. (2018). Galectin-3 as a potential marker of myocardial hypertrophy in essential hypertension in individuals with polymorphic AT1R genotypes. Biomedical Research and Therapy, 5(8), 2633-2644. https://doi.org/10.15419/bmrat.v5i8.471
Pashkova, Yu. P., Zhebel, N. V., Antomonov, M. Yu., Sakovych, O. O., Starzhynska, O. L., Zhebel, V. M., Palahniuk, H. O., & Syvak, V. H. (2016). Sposib prohnozuvannia ryzyku rozvytku khronichnoi sertsevoi nedostatnosti na tli hipertonichnoi khvoroby u cholovikiv 40-60 rokiv [Method for predicting risk of chronic heart failure against hypertension in men of 40-60 years]. Ukraine Patent UA 112123. https://base.uipv.org/searchINV/search.php?action=viewdetails&IdClaim=225432&chapter=biblio
Yunkerov, V. I, & Grigoriev, S. G. (2002). Matematiko-statisticheskaya obrabotka dannykh meditsinskikh issledovanii [Mathematical and statistical processing of medical research data]. Voenno-med. akad. [in Russian].
Berezin, A. E. (2017). Sovremennaya strategiya ispol'zovaniya biologicheskikh markerov v diagnostike i stratifikatsii patsientov s ostroi i khronicheskoi serdechnoi nedostatochnost'yu [A modern strategy for the use of biological markers in the diagnosis and stratification of patients with acute and chronic heart failure]. Sertseva nedostatnist ta komorbidni stany, (3), 12-23. [in Russian].
Rørth, R., Jhund, P. S., Kristensen, S. L., Desai, A. S., Køber, L., Rouleau, J. L., Solomon, S. D., Swedberg, K., Zile, M. R., Packer, M., & McMurray, J. (2019). The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. European Journal of Heart Failure, 21(1), 40-49. https://doi.org/10.1002/ejhf.1359
Verbovoy, A. F., & Barabanova, N. A. (2017). Diagnosticheskaya i prognosticheskaya tsennost' opredeleniya N-terminal'nogo fragmenta mozgovogo natriiureticheskogo peptida u bol'nykh sakharnym diabetom 2-go tipa [Diagnostic and prognostic value of detection of the N-terminal fragment of brain natriuretic peptide in type 2 diabetes mellitus]. Klinicheskaya meditsina, 95(6), 553-557. https://doi.org/10.18821/0023-2149-2017-95-6-553-557 [in Russian].
Kirillova, V., Sokolova, L. A., Meshchaninov, V. N., & Pershanova, V. I. (2018). Uroven' NT-proBNP u ambulatornykh patsientov s khronicheskoi serdechnoi nedostatochnost'yu i sokhranennoi fraktsiei vybrosa levogo zheludochka [The level of NT-proBNP in ambulatory patients with chronic heart failure with preserved ejection fraction of the left ventricle]. Terapevticheskii arkhiv, 90(9), 68-72. https://doi.org/10.26442/terarkh201890968-72 [in Russian].
Kremzer, A. A. (2014). Diagnosticheskaya tsennost' urovnya mozgovogo natriiureticheskogo peptida kak indikatora tyazhesti khronicheskoi serdechnoi nedostatochnosti ishemicheskogo geneza u patsientov s sakharnym diabetom 2-go tipa [Diagnostic value of brain natriuretic peptide as indicator of ischemic chronic heart failure severity in diabetes mellitus 2 types patients]. Ukrainskyi kardiolohichnyi zhurnal, (3), 82-88. [in Ukrainian].
Mareev, Yu. V., Garganeeva, A. A., Tukish, O. V., Rebrova, T. Yu., Anikina, D. V., & Mareev, V. Yu. (2019). Slozhnosti v diagnostike serdechnoi nedostatochnosti s sokhranennoi fraktsiei vybrosa v real'noi klinicheskoi praktike: dissonans mezhdu klinikoi, ekhokardiograficheskimi izmeneniyami, velichinoi natriiureticheskikh peptidov i shkaloi H2FPEF [Difficulties in diagnosis of heart failure with preserved ejection fraction in clinical practice: dissonance between echocardiography, NTproBNP and H2HFPEF score]. Kardiologiia, 59(12S), 37-45. https://doi.org/10.18087/cardio.n695 [in Russian].
Magnusson, M., Jovinge, S., Shahgaldi, K., Israelsson, B., Groop, L., & Melander, O. (2010). Brain natriuretic peptide is related to diastolic dysfunction whereas urinary albumin excretion rate is related to left ventricular mass in asymptomatic type 2 diabetes patients. Cardiovascular Diabetology, 9, Article 2. https://doi.org/10.1186/1475-2840-9-2
Edvinsson, M.-L., Ahnstedt, H., Edvinsson, L., & Andersson, S. E. (2016). Characterization of Relaxant Responses to Natriuretic Peptides in the Human Microcirculation In Vitro and In Vivo. Microcirculation, 23(6), 438-446. https://doi.org/10.1111/micc.12290
Wong, L. L., Wee, A. S., Lim, J. Y., Ng, J. Y., Chong, J. P., Liew, O. W., Lilyanna, S., Martinez, E. C., Ackers-Johnson, M. A., Vardy, L. A., Armugam, A., Jeyaseelan, K., Ng, T. P., Lam, C. S., Foo, R. S., Richards, A. M., & Chen, Y. T. (2015). Natriuretic peptide receptor 3 (NPR3) is regulated by microRNA-100. Journal of Molecular and Cellular Cardiology, 82, 13-21. https://doi.org/10.1016/j.yjmcc.2015.02.019
Vaes, B., Gruson, D., Van Pottelbergh, G., Pasquet, A., Matheï, C., Adriaensen, W., Rezzoug, N., Vanoverschelde, J. L., & Degryse, J. (2012). The impact of confounders on the test performance of natriuretic peptides for cardiac dysfunction in subjects aged 80 and older. Peptides, 38(1), 118-126. https://doi.org/10.1016/j.peptides.2012.08.020
Syvolap, V. D., Lashkul, D. A., Abramov, A. V., & Manukyan, A. M. (2014). Mozgovoi natriiureticheskii peptid i strukturno-funktsional'noe remodelirovanie serdtsa pri khronicheskoi serdechnoi nedostatochnosti s izbytochnoi massoi tela i ozhireniem [Brain natriuretic peptide, structural and functional cardiac remodeling in chronic heart failure with overweight and obesity]. Zaporozhye medical journal, (3), 9-12. https://doi.org/10.14739/2310-1210.2014.3.25595 [in Russian].
Oh, A., Okazaki, R., Sam, F., & Valero-Muñoz, M. (2019). Heart Failure With Preserved Ejection Fraction and Adipose Tissue: A Story of Two Tales. Frontiers in Cardiovascular Medicine, 6, Article 110. https://doi.org/10.3389/fcvm.2019.00110
Obokata, M., Reddy, Y., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017). Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation, 136(1), 6-19. https://doi.org/10.1161/CIRCULATIONAHA.116.026807
Stavrakis, S., Pakala, A., Thadani, U., Thomas, J., & Chaudhry, M. A. (2013). Obesity, Brain Natriuretic Peptide Levels and Mortality in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Systolic Function. The American Journal of the Medical Sciences, 345(3), 211-217. https://doi.org/10.1097/MAJ.0b013e318271c012
Clerico, A., Giannoni, A., Vittorini, S., & Emdin, M. (2012). The paradox of low BNP levels in obesity. Heart Failure Reviews, 17(1), 81-96. https://doi.org/10.1007/s10741-011-9249-z
Inoue, Y., Kawai, M., Minai, K., Ogawa, K., Nagoshi, T., Ogawa, T., & Yoshimura, M. (2016). The impact of an inverse correlation between plasma B-type natriuretic peptide levels and insulin resistance on the diabetic condition in patients with heart failure. Metabolism: Clinical and Experimental, 65(3), 38-47. https://doi.org/10.1016/j.metabol.2015.09.019
Prenner, S. B., & Mather, P. J. (2018). Obesity and heart failure with preserved ejection fraction: A growing problem. Trends in Cardiovascular Medicine, 28(5), 322-327. https://doi.org/10.1016/j.tcm.2017.12.003
Buckley, L. F., Canada, J. M., Del Buono, M. G., Carbone, S., Trankle, C. R., Billingsley, H., Kadariya, D., Arena, R., Van Tassell, B. W., & Abbate, A. (2018). Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction. ESC Heart Failure, 5(2), 372-378. https://doi.org/10.1002/ehf2.12235
Dal, K., Ata, N., Yavuz, B., Sen, O., Deveci, O. S., Aksoz, Z., Yildirim, A. M., Uygungelen, B., Akin, K. O., Beyan, E., & Ertugrul, D. T. (2014). The relationship between glycemic control and BNP levels in diabetic patients. Cardiology Journal, 21(3), 252-256. https://doi.org/10.5603/CJ.a2013.0109
Romano, S., Di Mauro, M., Fratini, S., Guarracini, L., Guarracini, F., Poccia, G., & Penco, M. (2010). Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides. Cardiovascular Diabetology, 9(1), Article 89. https://doi.org/10.1186/1475-2840-9-89
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
